| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
ABSTRACT |
|---|
|
|
|---|
Prevention of ischemia-reperfusion (IR) injury is crucial for successful lung transplantation. We investigated whether a nitric oxide donor, nitroglycerin (NTG), could suppress the oxidative stress of
IR injury and improve pulmonary function after reperfusion in an ex vivo rat lung perfusion model. In
Fresh group of animals, the lungs were flushed with perfusate, followed immediately by reperfusion,
and no lung injury was observed. In NTG
and NTG+ groups of animals, the lungs were flushed
with perfusate alone or perfusate containing NTG, respectively. Harvested lung and heart blocks
from these latter two groups were immersed in the corresponding perfusate at 4° C for 15 h, and
were then reperfused for 60 min. Reperfusion induced pulmonary edema in the NTG
group, but
not in the NTG+ group. Shunt fractions in NTG+ group were significantly lower than in the NTG
group throughout reperfusion. NTG had no effect on pulmonary arterial pressure or myeloperoxidase activity. In contrast, oxidative DNA damage assessed immunohistochemically with a monoclonal antibody against 8-hydroxy-2'-deoxyguanosine (8-OHdG) was significantly increased in the
NTG
group, in the order alveolar epithelium > pulmonary endothelium > bronchial epithelium.
NTG treatment significantly decreased staining with the anti-8-OHdG antibody in all three areas of
tissue. Therefore, administration of NTG attenuates the oxidative stress of IR injury, and may improve pulmonary function after reperfusion. Kawashima M, Bando T, Nakamura T, Isowa N, Liu
M, Toyokuni S, Hitomi S, Wada H. Cytoprotective effects of nitroglycerin in ischemia-reperfusion-induced lung injury.
| |
INTRODUCTION |
|---|
|
|
|---|
Lung transplantation has become an important modality for the treatment of end-stage lung disease. More than 1,000 lung-transplantation operations are now performed annually throughout the world (1). On the other hand, the shortage of lung donors, and ischemia-reperfusion (IR) injury following transplantation, have been grave problems in lung transplantation. To solve these problems, we have developed new organ-preservation solutions that can prevent tissue damage and extend ischemic periods with satisfactory results (2).
Nitric oxide (NO) has many physiologic activities, including a vasodilatory effect (6), inhibition of adhesion and migration of neutrophils to the vascular wall (7), and a protective action against cell damage caused by reactive oxygen species (ROS) (8). NO released from endothelial cells activates soluble guanylate cyclase in vascular smooth-muscle cells, with consequent production of cyclic guanosine-3',5'-monophosphate (cGMP), and plays an important role in maintaining the function of blood vessels (9). However, when endothelial cells are exposed to IR, endogenous NO reacts with superoxide, which is produced rapidly during reoxygenation, drastically reducing the available quantity of NO. Consequently, the tissue cGMP concentration falls, and vascular function deteriorates (10).
Inhaled NO (11), and NO donors such as N
-nitro-L-arginine methyl ester and N
-nitro-D-arginine methyl ester (12), attenuate IR injury. Nitroglycerin (NTG), another NO donor,
improves lung preservation for transplantation (13). Because
NTG has been used as a vasodilator through its release of NO
for a prolonged period (14), it may be suitable for the supplementation of lung preservation solutions. Administration of
NTG during the initial reperfusion of lung grafts has been reported to improve pulmonary function after reperfusion (15). However, the direct mechanisms by which NTG protects lung
tissue against injury are unknown.
During IR, ROS are produced in massive amounts resulting in tissue damage. ROS also cause DNA damage and produce various oxidatively modified products (16). Of these products, 8-hydroxy-2'-deoxyguanosine (8-OHdG) is one of the most popular markers for the evaluation of oxidative damage to DNA (17). Although 8-OHdG has been measured with an electrochemical detector connected to a high-pressure liquid chromatography (HPLC) system, localization of oxidative DNA damage was not possible with this method, and artifacts generated during sample preparation have been a subject of debate (18). Subsequently, a monoclonal antibody (mAb) (N45.1) that has a high affinity for 8-OHdG was developed (19). In situ quantification of oxidative damage to DNA (8-OHdG Index) in tissues has become feasible through immunohistochemical staining with this antibody. Data obtained with this method correlate well with HPLC results. Furthermore, this method produces fewer artifacts than the HPLC method (17).
In the present study we investigated: (1) whether supplementation of an organ preservation solution with NTG could maintain the cGMP level in lung tissue during cold ischemia, and consequently improve postreperfusion pulmonary function; and (2) whether supplementation with NTG could attenuate oxidative DNA damage to reperfused lung, as evaluated with the 8-OHdG Index. An ex vivo perfusion circuit was used (20). With this model, we evaluated the hemodynamics and gas exchange of preserved lung during reperfusion, using mixed venous blood obtained from rats as a perfusate and the isolated lung as a biologic deoxygenator (3, 21).
| |
METHODS |
|---|
|
|
|---|
Preservation Solution and Drugs
Extracellular-type Kyoto (ET-K) solution, which was used in the study, is an organ preservation solution with an ionic composition similar to that of extracellular fluid, and is supplemented with the nonreducing disaccharide trehalose, which has a cell membrane-protective effect (22). The composition of ET-K solution includes Na+, 100 mM; K+, 44 mM; gluconate, 100 mM; phosphate, 25 mM; trehalose, 4.1%, and hydroxyethyl starch, 3%. Its osmolarity is 366 mOsm/L, and its pH is 7.40. NTG was purchased from Green Cross, Ltd. (Osaka, Japan), and prostaglandin E1 (PGE1) was kindly provided by Ono Pharmaceutical, Ltd. (Osaka, Japan).
Donor and Deoxygenator Lung Preparation
All animals received humane care in compliance with the Guide for the Care and Use of Laboratory Animals prepared by the National Institutes of Health (23). Surgical procedures were performed as described (3, 21), using inbred male Lewis rats (280 to 300 g; Seac Yoshitomi, Ltd., Fukuoka, Japan). Rats were anesthetized by intraperitoneal injection of sodium pentobarbital (30 mg/kg), and were intubated after tracheostomy. Ventilation conditions during surgery were maintained with room air at a tidal volume (VT) of 3.0 ml and a respiratory rate (RR) of 60 breaths/min, using a volume-controlled respirator (Model SN480-7; Shinano, Tokyo, Japan). After a median abdominal incision was made, donor rats were heparinized (400 units) via the inferior vena cava. A median sternotomy was performed and a 14-gauge pulmonary arterial cannula was inserted into right ventricular outflow tract. The abdominal aorta and vena cava, right and left ventricles, and left atrial appendage were incised to facilitate free flow of pulmonary venous blood. Positive end-expiratory pressure (PEEP) at 2 cm H2O was then applied to the airway. For donor lung, the pulmonary vascular bed was flushed with the perfusate (4° C, 50 ml) containing PGE1 (10 µg), at a pressure of 20 cm H2O. After harvesting of the heart-lung block, airway pressure was kept at 14 cm H2O, the trachea was clamped, and the right pulmonary hilus was ligated. The right upper and middle lobes were resected and frozen for measurement of tissue cGMP level. The heart-lung block was then immersed in the preservation solution at 4° C.
For deoxygenator lungs, harvesting was done as with the donor lungs, but without the flushing procedure. Both sides of lungs were used as deoxygenators.
Perfusion Circuit
We used an ex vivo rat lung perfusion model first described by DeCampos and colleagues (Figure 1) (20). The perfusion circuit was filled with 40 ml of fresh heparinized blood taken from three rats. The blood was kept at 37° C. Right lower and mediastinal lobes of the lungs used for experimentation were resected for measurement of tissue cGMP level immediately after cold preservation for 15 h. The left lung was placed in a chamber maintained at 37° C with a humidity of 100%. The left lung was ventilated at an inspired oxygen fraction (FIO2) of 1.0, VT of 1.5 ml, and RR of 40 breaths/min, with a PEEP of 2 cm H2O. The deoxygenator lung was maintained under the same conditions and ventilated with mixed gas (FIO2 = 0.04, inspired carbon dioxide fraction = 0.08, and inspired nitrogen fraction = 0.88) at a VT of 3.0 ml and a RR of 60 breaths/min, with a PEEP of 2 cm H2O. The blood deoxygenated by the deoxygenator lung was perfused through the experimental lung for oxygenation and was then recirculated to the deoxygenator lung with a roller pump (Model 7553-80; Cole Parmer Instrument Co., Chicago, IL). The flow rate of perfusion was gradually increased to 4 ml/min over the initial 10 min, and was maintained at 4 ml/min thereafter, until the end of the study. The perfused blood was adjusted with sodium bicarbonate if necessary to keep the pH of blood returning from the deoxygenator lung between 7.35 and 7.45.
|
When severe pulmonary edema of the experimental lung occurred and fluid exuded from the tracheal tube, reperfusion was discontinued.
Experimental Groups
Rats were allocated to each of three groups at random. In Fresh group
(n = 7), lungs were flushed only with ET-K solution and were immediately reperfused for 60 min. In the groups designated NTG+ (n = 10) and NTG
(n = 10), lungs were flushed with the perfusate with
and without NTG (0.44 mM), respectively, before being immersed in
the corresponding solution for 15 h at 4° C and reperfused for 60 min.
Physiologic Measurements
Pulmonary venous blood from the lung used for experimentation or
from the deoxygenator lung, coming from the incised left atrium and
ventricle, was collected for blood gas analysis. The analyses were performed immediately before reperfusion and then every 10 min during
reperfusion, with an automatic blood gas analyzer (ABL300; Radiometer A/S, Copenhagen, Denmark). The data were used to calculate
the pulmonary shunt fraction (
S/
T) with the following formula:
|
(1) |
where Cc, Ca, and Cv represent the oxygen content of pulmonary capillary, pulmonary arterial, and pulmonary venous blood, respectively.
Mean pulmonary arterial pressure (
) and peak inspiratory airway
pressure (Ppi) were monitored continuously and recorded at 10-min intervals with a pressure-monitoring system (AP-641G; Nihon Kohden,
Tokyo, Japan). The lower one-third of the left lung was resected at the
end of reperfusion, and the wet tissue was weighed. The tissue was then
dried at 55° C for 72 h, the dry tissue was weighed, and the wet-to-dry
weight ratio of the lung tissue (W/D ratio) was calculated. For assessment of stability of the ex vivo perfusion system, the W/D ratio of the
left lung tissue of the deoxygenator lung was evaluated similarly.
cGMP Assay
For cGMP assays, right upper and middle lobes excised immediately after flushing, right lower and mediastinal lobes excised before reperfusion, and one-third of the left lung excised after reperfusion were snap frozen in liquid nitrogen and kept until the time of assay for tissue cGMP level. The lung tissue samples used for assay were homogenized in ice-cold 0.1 N HCl (2 ml). After centrifuging the homogenates at 3,000 × g for 15 min at 4° C, we measured cGMP in the supernatants with a radioimmunoassay kit (cGMP Assay kit; Yamasa, Chiba, Japan). Results were reported as picomoles of cGMP per milligram of protein. The protein content of samples was quantified according to the method of Lowry and coworkers (24).
Myeloperoxidase Assay
A myeloperoxidase (MPO) assay was done on the experimental lungs that were resected 60 min after reperfusion and snap frozen in liquid nitrogen until the assay. Tissue was homogenized in 2 ml of potassium phosphate buffer (50 mM, pH 6) containing hexadecyltrimethylammonium bromide (0.5%; Sigma Chemical Co., St. Louis, MO). The sample was centrifuged at 12,000 × g for 10 min, and the supernatant was decanted. The MPO activity in each sample was measured with a standard chromogenic spectrophotometric technique (25).
Immunohistochemistry with Monoclonal Antibody N45.1
Sample tissues from the lungs for experimentation were fixed overnight with Bouin's solution after reperfusion for 60 min. In addition,
normal lung tissues from three rats that were anesthetized and ventilated with room air were fixed at identical settings immediately after
excision, so that the lungs had neither been subjected to flushing nor
to preservation or reperfusion. The avidin-biotin complex method
(26), with a slight modification, was used for immunohistochemical
staining. After deparaffinization of lung tissue with xylene and ethanol, normal rabbit serum (diluted to 1:75; Dako, Kyoto, Japan) was
used to block nonspecific binding, and mAb N45.1 (0.5 µg/ml), biotin-labeled rabbit antimouse IgG serum (diluted to 1:300; Dako), and avidin-biotin-alkaline phosphatase complex (diluted to 1:100; Dako)
were sequentially applied. The final color development reaction was
run simultaneously for 24 specimens (nine specimens from the NTG+
group, eight from the NTG
group, four from the Fresh group, and
three from normal lungs).
To confirm the specificity of immunostaining, we conducted the 8-OHdG absorption tests by incubating an excess of 8-OHdG (final concentration, 500 µM; Wako, Osaka, Japan) with the primary antibody on glass slides. Alternatively, to produce a negative control, we omitted the first antibody from the staining procedure.
Quantification of Immunohistologic Data
Quantification of immunohistologic data was done as previously described, with the 8-OHdG Index (17). For this purpose, specimens for 8-OHdG immunohistochemistry were used for densitometric analysis. Color slides (35 mm) of three appropriate locations, which were focused on bronchial epithelial cells (Br-EC), alveolar epithelial lining cells (Al-EC), or pulmonary arterial endothelial cells (Pa-EC), were taken of each specimen at a magnification of 40 × 5, covering an area of approximately 335 µm × 220 µm. Color images were obtained as PICT files with a slide scanner (Quick Scan; Minolta, Tokyo, Japan) connected to a Power Macintosh 8500/1200 computer (Apple Computer Japan, Inc., Tokyo, Japan). The brightness and contrast of each image file were uniformly enhanced with Adobe Photoshop version 3.0J, followed by image analysis done with NIH Image freeware (version 1.61; National Institutes of Health, Bethesda, MD; available on the internet via a file transfer protocol from zippy.nimh. nih.gov). The following equation was used for quantification of immunohistochemical data:
|
(2) |
where X is staining density, indicated by a number between 0 and 256 on the Gray scale. Specimens in the three groups were analyzed for Br-EC and Al-EC within a particular respiratory area, and for Pa-EC within a particular vessel area, respectively. The mean of the data obtained from three independent files was used as a representative value for each animal.
Statistical Analysis
All results are presented as mean ± SEM. Comparison of groups with more than two representatives was done through one-way or two-way analysis of variance (ANOVA), followed by the Student-Newman- Keuls test (27), with significance defined at p < 0.05. Comparison of two groups was done with Student's t test. These analyses were done with an IBM PC computer (IBM Japan, Ltd., Tokyo), using SigmaStat for Windows, version 1.0 (Jandel Corporation, San Rafael, CA).
| |
RESULTS |
|---|
|
|
|---|
All lungs from animals in the Fresh and NTG+ groups were
reperfused throughout the entire 60-min observation period.
However, ventilation of one lung from the NTG
group (n = 10) was discontinued after 50 min of reperfusion because of
severe pulmonary edema.
The Stability of the Ex Vivo Perfusion System
Hemoglobin levels of the priming blood in the perfusion circuit were 13.7 ± 0.7 mg/dl in the Fresh group, 14.3 ± 0.3 mg/dl in the NTG+ group, and 14.3 ± 0.2 mg/dl in the NTG
group,
with no significant differences among the three groups. There
was no significant difference in the blood gas analysis data for
blood from the deoxygenator lungs of the three study groups
before and throughout the reperfusion perfusion (Table 1).
The W/D ratios of the deoxygenator lungs after reperfusion
were 6.5 ± 1.3 in the Fresh group, 6.9 ± 1.0 in the NTG+
group, and 6.1 ± 0.4 in the NTG
group, with no significant
differences among the three groups. Thus, the ex vivo perfusion system was very stable through the experimental period.
|
Lungs Perfused without NTG Showed Features of IR Injury
In the Fresh group, lungs reperfused immediately after harvesting, without preservation, showed good pulmonary function. The W/D ratio for these lungs was 6.2 ± 0.6 (Figure 2),
resembling that of normal lungs, as we previously reported (3,
21). Shunt fractions remained at 4% to 6% (Figure 3).
and Ppi values were within 15 to 16 mm Hg and 11 to 12 mm
Hg of one another, respectively (Figure 4), during the 60-min
reperfusion period. In the absence of NTG, reperfusion induced severe pulmonary edema and deterioration of pulmonary function. W/D ratios in the NTG
group increased by
about threefold over those of the Fresh group, indicating severe pulmonary edema (Figure 2). During the reperfusion, the
shunt fractions gradually increased by up to 40%, and the Ppi
values were over 20 mm Hg (Figures 3 and 4B). On the other hand,
values did not change very greatly throughout the
reperfusion period (Figure 4A).
|
|
|
Supplementation of the Perfusate with NTG Improved Pulmonary Function after Reperfusion
In the NTG+ group, NTG was added to both the flush and
the preservation solutions. A significant improvement in gas
exchange was observed over that in the NTG
group. Shunt
fractions were significantly lower than those in NTG
group
until 50 min after reperfusion (Figure 3). There were no significant differences in shunt fractions between the NTG+ and
Fresh groups. W/D ratios were significantly lower than those
in the NTG
group (p < 0.05) (Figure 2). Interestingly,
was unaffected by NTG treatment (Figure 4A), whereas values of Ppi were significantly lower than those in NTG
group
throughout the experiment (Figure 4B).
Insufficient Inhibitory Effect of NTG against Neutrophil Infiltration
MPO activity has been commonly used as a marker for neutrophil infiltration and activation during acute inflammatory
responses. We found no significant difference in MPO activity
between the NTG+ group (254.9 ± 41.0 U/mg protein) and
the NTG
group (295.8 ± 51.2 U/mg protein). The MPO assay was not done in the Fresh group.
Changes In Tissue cGMP Level during Preservation and Reperfusion
Levels of cGMP in lung tissue declined during preservation
and reperfusion. In the NTG
group, tissue cGMP levels decreased to about one-third of those immediately after flushing
following preservation of tissue at 4° C for 15 h, and to less
than one-ninth of the levels after flushing following reperfusion for 60 min (Figure 5). NTG added to the perfusate maintained tissue cGMP levels after preservation at significantly
higher values than those in the NTG
group (p < 0.05), but
did not maintain cGMP levels during reperfusion (Figure 5).
|
Immunohistochemical Detection of Sites of Oxidative Damage Caused by IR Injury
In normal lung, nuclear staining with mAb N45.1 was barely
detectable. Reperfusion without hypothermic preservation
slightly increased the staining. Oxidative damage caused by IR
injury was found in both airway epithelium and blood vessel
endothelium. In the NTG
group, intense nuclear staining of
bronchial epithelial cells, alveolar epithelial cells, and pulmonary endothelial cells was observed. NTG treatment significantly inhibited the IR-induced oxidative damage seen in the
NTG
group (Figures 6-8). No staining was observed
either when the N45.1 antibody was omitted or when the primary antibody applied to the slides was preabsorbed with an
excess of 8-OHdG (data not shown).
|
|
|
Quantification of Oxidative DNA Damage in Postreperfusion Lung
Oxidative DNA damage in Al-EC was much more severe than
that to the other two types of cells examined. In the NTG
group, 8-OHdG Indices of Al-EC were about fivefold greater
than those of Br-EC (p < 0.05) when quantified by morphometric analysis (Figure 9). Supplementation of the perfusate
with NTG attenuated oxidative stress caused by IR injury.
8-OHdG Indices of the NTG
group were 12 times greater in
Al-EC, 19 times greater in Pa-EC, and six times greater in Br-EC, respectively, than those of the NTG+ group. In the Fresh
group, 8-OHdG indices for all three areas were below 20, and
were significantly below those in the NTG
group (Figure 9).
|
| |
DISCUSSION |
|---|
|
|
|---|
Endogenously produced NO stimulates production of cGMP,
which acts as an intracellular second messenger in relaxing
vascular smooth muscle (9), inhibiting platelet adhesion and
aggregation (28), and adjusting vascular permeability (29).
Levels of endogenous NO produced in the lung and heart
have been reported to be decreased during preservation and
reperfusion, through a response to ROS generated from alveolar macrophages and neutrophils (10). NTG is known to
work in vivo as an NO donor. Intravenous infusion of NTG
into rabbits (30, 31) or lambs (32) induced dose-dependent increments in exhaled NO and concomitant reductions in systemic blood pressure. Marczin and colleagues showed that intravenous administration of NTG resulted in an increase in
exhaled NO that coincided with a reduction of arterial blood
pressure in patients undergoing open heart surgery (33). In
the present study, cGMP levels in lung tissues decreased during preservation in the NTG
group. Supplementation of the
perfusate with NTG maintained tissue cGMP levels during
cold preservation, indicating that NTG may play a role as an
NO donor during lung preservation for 15 h. David and coworkers reported that the effect of NTG could persist for 18 to
24 h (14). The tissue cGMP level in the NTG+ group diminished after reperfusion. The volume of the vascular bed of the
rat left lung is estimated to be approximately 1 ml, and the total blood volume in the perfusion circuit was about 40 ml. Preservation solution in the vascular bed is promptly washed out at
the beginning of reperfusion. Consequently, the amount of
NTG within the pulmonary vascular bed is quite small. Furthermore, the production of NO seen in normal lung may be
inhibited by ROS produced by IR. Hogg and coworkers demonstrated that endogenous NO reacts directly with superoxide
at the endothelial surface during reperfusion, to produce hydroxyl radical (34). Therefore, the higher tissue cGMP level in
the NTG+ group in our study could not be maintained during reperfusion.
Nevertheless, addition of NTG to the preservation solution
protected lungs against severe IR-induced pulmonary edema
and dysfunction. The shunt fraction and Ppi in the NTG
group gradually increased over the course of reperfusion, and
the W/D ratio in this group was significantly higher than that
in the Fresh group. Addition of NTG improved shunt fractions throughout reperfusion, which were significantly better
than the fractions in the NTG
group. By contrast, NTG had
no effect on
or MPO activity in our study. These results
suggest that the protective effects of NTG in preservation solution may be not related to vasodilation or inhibition of neutrophil adhesion or activation.
NTG may function via a cGMP-independent mechanism (35). Zhou and associates showed that relaxation of canine trachea induced by the NO donor sodium nitroprusside was potentiated by methylene blue and hemoglobin, which reduced cGMP accumulation (34). Another NO donor, S-nitrosoglutathione, was also reported to relax canine tracheal smooth muscle, in part through a cGMP-independent process (36). It was recently reported that NO could induce the synthesis of glutathione, an important intracellular antioxidant, through a cGMP-independent pathway (37).
Our results demonstrate a strong correlation between the
inhibition of oxidative DNA damage as quantified with the
8-OHdG Index and improved postreperfusion pulmonary
function in our NTG+ group. 8-OHdG Indices in the Fresh
group were very low, and those in the NTG
group were significantly increased in all three cell areas that we examined.
NTG treatment blocked the increase in the 8-OHdG index,
keeping it at to the levels seen in the Fresh group. NTG has
been reported to have a cytoprotective effect on H2O2-induced
endothelial dysfunction in cell culture (38), to improve rat lung
preservation through antineutrophil and antiplatelet (13), and
to reduce plasma malondialdehyde levels after thrombolytic therapy for acute myocardial infarction (39). The cytoprotective effect of NTG seen in the present in study may contribute
significantly to the amelioration of IR injury of the lung. NO
has been suggested to have a protective effect against damage
caused by ROS (8). Inhaled NO inhibits capillary damage caused
by oxygen radicals (40).
8-OHdG Indices for the NTG
group in our study were in
the order Al-EC > Pa-EC > Br-EC; accordingly, oxidative
damage to DNA in alveoli was the most severe among the
three areas that we examined. This result may be attributable
to the following events: (1) During preservation, endothelia in
the vascular bed are in direct contact with the preservation solution, which may have cell membrane-protective effects. (2)
After reperfusion, the capillary endothelial cells lining alveoli
are exposed to reperfusion flow. Damage to endothelial cells
may consequently affect alveolar epithelial cell function. In
addition, alveolar epithelial cells are exposed to a high concentration of oxygen, and alveoli can therefore also be damaged directly through the respiratory tract. (3) When exposed
to oxygen, alveolar epithelial cells are more readily affected
by oxidative stress than are bronchial epithelial cells, because
type I alveolar epithelial cells are flatter and have a larger surface area than bronchial epithelial cells (41). (4) The respiratory tract lining fluid contains antioxidants such as mucin, uric
acid, and reduced glutathione, and the thickness of the lining
fluid layer decreases from bronchi to alveoli (41). In this
study we focused on pulmonary arterial endothelium to evaluate DNA damage. Recently, Khimenko and Taylor reported
that the greatest damage occurred within postalveolar venules
in isolated perfused rat lung after IR (44). Prudent observation of small vessels will further elucidate the predominant site of injury from IR.
In summary, a cytoprotective effect of NTG given during flushing and preservation of lung was observed in alveolar and bronchial epithelial cells, as well as in pulmonary arterial endothelial cells, after reperfusion. This cytoprotective effect was associated with and may contribute to amelioration of IR-induced lung injury. NTG could be a potent additive to preservation solutions for attenuating DNA damage caused by oxidative stress, thereby protecting against reperfusion injury during lung transplantation.
| |
Footnotes |
|---|
Correspondence and requests for reprints should be addressed to Hiromi Wada, M.D., Ph.D., Department of Medical Systems Control, Field of Medical Systems Engineering, Institute for Frontier Medical Sciences and Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Shogoin Kawahara-cho 53, Sakyo-ku, Kyoto 606-8397, Japan. E-mail: wada{at}frontier.kyoto-u.ac.jp
(Received in original form May 3, 1999 and in revised form August 9, 1999).
Dr. Isowa is the recipient of a fellowship from the Department of Surgery and Faculty of Medicine, University of Toronto.Acknowledgments: The authors extend their appreciation to Dr. Tadayuki Saito (New Drug Discovery Research Laboratory, Kanebo, Ltd., Osaka, Japan) for his kind advice about the measurement of MPO activity, and to Dr. Nobuyuki Hamajima (Aichi Cancer Center Research Institute, Nagoya, Japan) for his kind advice about the statistical analyses. Prostaglandin E1 was provided by Ono Pharmaceutical Co., Ltd., Osaka, Japan.
| |
References |
|---|
|
|
|---|
1.
Hosenpud, J. D.,
R. J. Novick,
L. E. Bennett,
B. M. Keck,
B. Fiol, and
O. P. Daily.
1996.
The Registry of the International Society for Heart
and Lung Transplantation: Thirteenth Official Report
1996.
J. Heart
Lung Transplant.
15:
655-674
[Medline].
2.
Bando, T.,
S. Kosaka,
C. Liu,
T. Hirai,
T. Hirata,
H. Yokomise,
K. Yagi,
K. Inui,
S. Hitomi, and
H. Wada.
1994.
Effects of newly developed solutions containing trehalose on twenty-hour canine lung preservation.
J. Thorac. Cardiovasc. Surg.
108:
92-98
3. Fukuse, T., T. Hirata, M. Ueda, S. Hitomi, and H. Wada. 1996. Effects of Euro-Collins, University of Wisconsin, and new extracellular-type trehalose-containing Kyoto solutions in an ex vivo rat lung preservation model. Transplantation 62: 1212-1217 [Medline].
4.
Liu, C. J.,
M. Ueda,
S. Kosaka,
T. Hirata,
H. Yokomise,
K. Inui,
S. Hitomi, and
H. Wada.
1996.
A newly developed solution enhances thirty-hour preservation in a canine lung transplantation model.
J. Thorac.
Cardiovasc. Surg.
112:
569-576
5.
Wada, H.,
C. J. Liu,
T. Hirata,
T. Bando, and
S. Kosaka.
1996.
Effective
30-hour preservation of canine lungs with modified ET-Kyoto solution.
Ann. Thorac. Surg.
61:
1099-1105
6. Furchgott, R. F., and J. V. Zawadzki. 1980. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376 [Medline].
7.
Kubes, P.,
M. Suzuki, and
D. N. Granger.
1991.
Nitric oxide: an endogenous modulator of leukocyte adhesion.
Proc. Natl. Acad. Sci. U.S.A.
88:
4651-4655
8.
Wink, D. A.,
I. Hanbauer,
M. C. Krishna,
W. DeGraff,
J. Gamson, and
J. B. Mitchell.
1993.
Nitric oxide protects against cellular damage and
cytotoxicity from reactive oxygen species.
Proc. Natl. Acad. Sci. U.S.A.
90:
9813-9817
9. Adrin, J. H., and L. J. Ignarros. 1997. The nitric oxide-cyclic GMP single transduction system. In W. M. Zapol and K. D. Bloch, editors. Nitric Oxide and the Lung. Marcel Dekker, New York. 1-57.
10.
Pinsky, D. J.,
Y. Naka,
N. C. Chowdhury,
H. Liao,
M. C. Oz,
R. E. Michler,
E. Kubaszewski,
T. Malinski, and
D. M. Stern.
1994.
The nitric oxide/cyclic GMP pathway in organ transplantation: critical role in
successful lung preservation.
Proc. Natl. Acad. Sci. U.S.A.
91:
12086-12090
11.
Okabayashi, K.,
A. N. Triantafillou,
M. Yamashita,
M. Aoe,
S. R. DeMeester,
J. D. Cooper, and
G. A. Patterson.
1996.
Inhaled nitric oxide
improves lung allograft function after prolonged storage.
J. Thorac.
Cardiovasc. Surg.
112:
293-299
12.
Moore, T. M.,
P. L. Khimenko,
P. S. Wilson, and
A. E. Taylor.
1996.
Role of nitric oxide in lung ischemia and reperfusion injury.
Am. J. Physiol.
271:
H1970-H1977
13.
Naka, Y.,
N. C. Chowdhury,
H. Liao,
D. K. Roy,
M. C. Oz,
R. E. Michler, and
D. J. Pinsky.
1995.
Enhanced preservation of orthotopically transplanted rat lungs by nitroglycerin but not hydralazine: requirement for graft vascular homeostasis beyond harvest vasodilation.
Circ. Res.
76:
900-906
14. David, G. H., and N. B. James. 1993. The nitrovasodilators: new ideas about old drugs. Circulation 87: 1461-1467 [Medline].
15.
Bhabra, M. S.,
D. N. Hopkinson,
T. E. Shaw, and
T. L. Hooper.
1997.
Attenuation of lung graft reperfusion injury by a nitric oxide donor.
J.
Thorac. Cardiovasc. Surg.
113:
327-333
16. Halliwell, B., and O. I. Aruoma. 1991. DNA damage by oxygen-derived species: its mechanism and measurement in mammalian systems. FEBS Lett. 281: 9-19 [Medline].
17. Toyokuni, S., T. Tanaka, Y. Hattori, Y. Nishiyama, A. Yoshida, K. Uchida, H. Hiai, H. Ochi, and T. Osawa. 1997. Quantitative immunohistochemical determination of 8-hydroxy-2'-deoxyguanosine by a monoclonal antibody, N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab Invest. 76: 365-374 [Medline].
18. Lindahl, T.. 1993. Instability and decay of the primary structure of DNA. Nature 362: 709-715 [Medline].
19. Osawa, T., A. Yoashida, S. Kawakishi, K. Yamashita, and H. Ochi. 1995. Protective role of dietary antioxidants in oxidative stress. Berkhauser Verlag, Basel. 367-377.
20.
DeCampos, K. N.,
S. H. Keshavjee,
L. Tremblay,
T. Yamashiro, and
A. S. Slutsky.
1996.
Use of a hypoxic lung as a deoxygenator to provide extended assessment of pulmonary function in rats.
J. Appl.
Physiol.
80:
1835-1840
21.
Nakamura, T.,
T. Hirata,
T. Fukuse,
M. Ueda,
S. Hitomi, and
H. Wada.
1997.
Dibutyryl cyclic adenosine monophosphate attenuates lung injury caused by cold preservation andischemia-reperfusion.
J. Thorac.
Cardiovasc. Surg.
114:
635-642
22.
Isowa, N.,
S. Hitomi, and
H. Wada.
1996.
Trehalose-containing solutions
enhance preservation of cultured endothelial cells.
Ann. Thorac. Surg.
61:
542-545
23. NIH Publication No. 86-23. Revised 1985. Bethesda, MD.
24.
Lowry, O.,
N. Rosebrough,
A. Farr, and
R. Randall.
1951.
Protein measurement with the Folin reagent.
J. Biol. Chem.
193:
265-275
25. Peter, P. B., A. P. Dennis, D. C. Robert, and R. Gerlad. 1982. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J. Invest. Dermatol 78: 206-209 [Medline].
26. Hsu, S. M., L. Raine, and H. Fanger. 1981. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 29: 577-580 [Abstract].
27. Snedecor, G. W., and W. G. Cochran. 1980. Statistical Methods, 8th ed. Iowa State University Press, Ames, IA.
28. Radomski, M. W., and S. Moncada. 1993. The biological and pharmacological role of nitric oxide in platelet function. Adv. Exp. Med. Biol. 344: 251-264 [Medline].
29. Westendorp, R. G., R. Draijer, A. E. Meinders, and V. W. van Hinsbergh. 1994. Cyclic-GMP-mediated decrease in permeability of human umbilical and pulmonary artery endothelial cell monolayers. J. Vasc. Res. 31: 42-51 [Medline].
30. Cederqvist, B., M. G. Persson, and L. E. Gustafsson. 1994. Direct demonstration of NO formation in vivo from organic nitrites and nitrates, and correlation to effects on blood pressure and to in vitro effects. Biochem. Pharmacol. 47: 1047-1053 [Medline].
31. Persson, M. G., P. Agvald, and L. E. Gustafsson. 1994. Detection of nitric oxide in exhaled air during administration of nitroglycerin in vivo. Br. J. Pharmacol. 111: 825-828 [Medline].
32. Husain, M., C. Adrie, F. Ichinose, M. Kavosi, and W. M. Zapol. 1994. Exhaled nitric oxide as a marker for organic nitrate tolerance. Circulation 89: 2498-2502 [Medline].
33. Marczin, N., B. Riedel, D. Royston, and M. Yacoub. 1997. Intravenous nitrate vasodilators and exhaled nitric oxide. Lancet 349: 1742 [Medline].
34. Hogg, N., V. M. Darley, Usmar, M. T. Wilson, and S. Moncada. 1992. Production of hydroxyl radicals from the simultaneous generation of superoxide and nitric oxide. Biochem J. 281: 419-424 .
35.
Zhou, H. L., and
T. J. Torphy.
1991.
Relationship between cyclic guanosine monophosphate accumulation and relaxation of canine trachealis induced by nitrovasodilators.
J. Pharmacol. Exp. Ther.
258:
972-978
36.
Perkins, W. J.,
C. Pabelick,
D. O. Warner, and
K. A. Jones.
1998.
cGMP-independent mechanism of airway smooth muscle relaxation induced
by S-nitrosoglutathione.
Am. J. Physiol.
275:
C468-C474
37. Moellering, D., J. McAndrew, R. P. Patel, H. J. Forman, R. T. Mulcahy, H. Jo, and V. M. Darley-Usmar. 1999. The induction of GSH synthesis by nanomolar concentrations of NO in endothelial cells: a role for gamma-glutamylcysteine synthetase and gamma-glutamyl transpeptidase. FEBS Lett. 448: 292-296 [Medline].
38. McQuaid, K. E., E. M. Smyth, and A. K. Keenan. 1996. Evidence for modulation of hydrogen peroxide-induced endothelial barrier dysfunction by nitric oxide in vitro. Eur. J. Pharmacol. 307: 233-241 [Medline].
39. Ohlin, H., N. Pavlidis, and A. K. Ohlin. 1998. Effect of intravenous nitroglycerin on lipid peroxidation after thrombolytic therapy for acute myocardial infarction. Am. J. Cardiol. 82: 1463-1467 [Medline].
40.
Guidot, D. M.,
M. J. Repine,
B. M. Hybertson, and
J. E. Repine.
1995.
Inhaled nitric oxide prevents neutrophil-mediated, oxygen radical-
dependent leak in isolated rat lungs.
Am. J. Physiol.
269:
L2-L5
41. Mercer, R. R., M. L. Russell, V. L. Roggli, and J. D. Crapo. 1994. Cell number and distribution in human and rat airways. Am. J. Respir. Cell Mol. Biol. 10: 613-624 [Abstract].
42. Cantin, A. M., G. A. Fells, R. C. Hubbard, and R. G. Crystal. 1990. Antioxidant macromolecules in the epithelial lining fluid of the normal human lower respiratory tract. J. Clin. Invest. 86: 962-971 .
43.
Bastacky, J.,
C. Y. Lee,
J. Goerke,
H. Koushafar,
D. Yager,
L. Kenaga,
T. P. Speed,
Y. Chen, and
J. A. Clements.
1995.
Alveolar lining layer
is thin and continuous: low-temperature scanning electron microscopy
of rat lung.
J. Appl. Physiol.
79:
1615-1628
44.
Khimenko, P. L., and
A. E. Taylor.
1999.
Segmental microvascular permeability inischemia-reperfusion injury in rat lung.
Am. J. Physiol.
276:
L958-L960
This article has been cited by other articles:
![]() |
D. Piquette, A. Deschamps, S. Belisle, M. Pellerin, S. Levesque, J.-C. Tardif, and A. Y. Denault Effect of intravenous nitroglycerin on cerebral saturation in high-risk cardiac surgery: [L'effet de la nitroglycerine intraveineuse sur la saturation cerebrale dans les chirurgies cardiaques a haut risque] Can J Anesth, September 1, 2007; 54(9): 718 - 727. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Omasa, S. Hasegawa, T. Bando, N. Hanaoka, T. Yoshimura, T. Nakamura, and H. Wada Application of ET-Kyoto solution in clinical lung transplantation Ann. Thorac. Surg., January 1, 2004; 77(1): 338 - 339. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. O. Meade, J. T. Granton, A. Matte-Martyn, K. McRae, B. Weaver, P. Cripps, and S. H. Keshavjee A Randomized Trial of Inhaled Nitric Oxide to Prevent Ischemia-Reperfusion Injury after Lung Transplantation Am. J. Respir. Crit. Care Med., June 1, 2003; 167(11): 1483 - 1489. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. de Perrot, M. Liu, T. K. Waddell, and S. Keshavjee Ischemia-Reperfusion-induced Lung Injury Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 490 - 511. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Rose, B. Guthmann, T. Tenenbaum, L. Fink, A. Ghofrani, N. Weissmann, P. Konig, L. Ermert, G. Dahlem, J. Haenze, et al. Apical, But Not Basolateral, Endotoxin Preincubation Protects Alveolar Epithelial Cells Against Hydrogen Peroxide-Induced Loss of Barrier Function: The Role of Nitric Oxide Synthesis J. Immunol., August 1, 2002; 169(3): 1474 - 1481. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. TOBIN Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1789 - 1804. [Full Text] [PDF] |
||||
![]() |
B. L. Upham and J. G. Wagner Toxicant-Induced Oxidative Stress in Cancer Toxicol. Sci., November 1, 2001; 64(1): 1 - 3. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Khatchatourian, C. Chevalley, A. Spiliopoulos, and M. Licker Myocardial revascularization and bilateral lung transplantation without cardiopulmonary bypass Eur. J. Cardiothorac. Surg., November 1, 2001; 20(5): 1042 - 1044. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Liu, L. Tremblay, S. D. Cassivi, X.-H. Bai, E. Mourgeon, A. F. Pierre, A. S. Slutsky, M. Post, and S. Keshavjee Alterations of nitric oxide synthase expression and activity during rat lung transplantation Am J Physiol Lung Cell Mol Physiol, May 1, 2000; 278(5): L1071 - L1081. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Cell Mol. Biol. |